click below
click below
Normal Size Small Size show me how
pharm-coag
pharmacology of coagulation
| Question | Answer |
|---|---|
| clopidogrel | reduce platelet aggregation by inhibiting ADP pathway of platelets |
| clopidogrel | used rot TIA, CVA and unstable angina |
| clopidogrel | anti-platelet effect lasts for 7-10 days |
| heparin | increases activity of antithrombin |
| heparin | releases lipoprotein lipase |
| heparin | used as prophylaxis for DVT; and to treat MI and PE |
| heparin | adverse effects--> bleeding, thrombocytopenia, hypersensititvity, reversible alopecia, osteoporosis |
| heparin | contraindications--> active bleeding, hemophilia, thrombocytopenia, HTN, purpura, before and after brain, spinla cord or eye surgery; no apirine, use caution during pregnancy |
| coumadin | highly teratogenic and fetotoxic |
| coumadin | clotting factors cannot bind Ca; blocks vit. K; factors II, VII, IX, X |
| coumadin | prohpylaxis of DVT's and PE's; A-fib |
| coumadin | adverse effects--> bleeding, hemorrhagic infarct in breast, intestine and fatty tissue |
| coumadin | interactions--> phenylbutazone and sulfinpyrazone- displaces from albumin; ASA- increases the action of coumadin; antibiotics- decreases vitamin K; barbituates and rifampin; decrease the effectiveness; oral contraceptives- decrease warfarin effectiveness |
| desmopressin acetate | increases factor VIII activity and can be used before minor surgeries in patients with mild hemophelia A |
| ASA | decreases thromboxane A2 production |
| ASA | reduce antithromotic action by decreasing endothelial cell synthesis of PGI2 |